These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29205704)

  • 1. Hypoglycemia in sulfonylurea-treated KCNJ11-neonatal diabetes: Mild-moderate symptomatic episodes occur infrequently but none involving unconsciousness or seizures.
    Lanning MS; Carmody D; Szczerbiński Ł; Letourneau LR; Naylor RN; Greeley SAW
    Pediatr Diabetes; 2018 May; 19(3):393-397. PubMed ID: 29205704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.
    Bowman P; Sulen Å; Barbetti F; Beltrand J; Svalastoga P; Codner E; Tessmann EH; Juliusson PB; Skrivarhaug T; Pearson ER; Flanagan SE; Babiker T; Thomas NJ; Shepherd MH; Ellard S; Klimes I; Szopa M; Polak M; Iafusco D; Hattersley AT; Njølstad PR;
    Lancet Diabetes Endocrinol; 2018 Aug; 6(8):637-646. PubMed ID: 29880308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Genetics, Clinical Characteristics, and Treatment Outcomes of K
    Ngoc CTB; Dien TM; De Franco E; Ellard S; Houghton JAL; Lan NN; Thao BP; Khanh NN; Flanagan SE; Craig ME; Dung VC
    Front Endocrinol (Lausanne); 2021; 12():727083. PubMed ID: 34566892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of postmeal insulin secretion in individuals with sulfonylurea-treated
    Bowman P; McDonald TJ; Knight BA; Flanagan SE; Leveridge M; Spaull SR; Shields BM; Hammersley S; Shepherd MH; Andrews RC; Patel KA; Hattersley AT
    BMJ Open Diabetes Res Care; 2019; 7(1):e000721. PubMed ID: 31908791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case report: Better late than never, but sooner is better: switch from CSII to sulfonylureas in two patients with neonatal diabetes due to KCNJ11 variants.
    Mancioppi V; Pozzi E; Zanetta S; Missineo A; Savastio S; Barbetti F; Mellone S; Giordano M; Rabbone I
    Front Endocrinol (Lausanne); 2023; 14():1143736. PubMed ID: 37251668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision Medicine: Long-Term Treatment with Sulfonylureas in Patients with Neonatal Diabetes Due to KCNJ11 Mutations.
    Letourneau LR; Greeley SAW
    Curr Diab Rep; 2019 Jun; 19(8):52. PubMed ID: 31250216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of KCNJ11 gene mutations in a family with neonatal diabetes mellitus: implications for therapeutic management of family members with long-standing disease.
    Abbasi F; Saba S; Ebrahim-Habibi A; Sayahpour FA; Amiri P; Larijani B; Amoli MM
    Mol Diagn Ther; 2012 Apr; 16(2):109-14. PubMed ID: 22471336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes.
    Thurber BW; Carmody D; Tadie EC; Pastore AN; Dickens JT; Wroblewski KE; Naylor RN; Philipson LH; Greeley SA;
    Diabetologia; 2015 Jul; 58(7):1430-5. PubMed ID: 25877689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADHD, learning difficulties and sleep disturbances associated with KCNJ11-related neonatal diabetes.
    Landmeier KA; Lanning M; Carmody D; Greeley SAW; Msall ME
    Pediatr Diabetes; 2017 Nov; 18(7):518-523. PubMed ID: 27555491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients.
    Ragia G; Tavridou A; Petridis I; Manolopoulos VG
    Diabetes Res Clin Pract; 2012 Oct; 98(1):119-24. PubMed ID: 22591706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes.
    Babiker T; Vedovato N; Patel K; Thomas N; Finn R; Männikkö R; Chakera AJ; Flanagan SE; Shepherd MH; Ellard S; Ashcroft FM; Hattersley AT
    Diabetologia; 2016 Jun; 59(6):1162-6. PubMed ID: 27033559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulfonylurea vs insulin therapy in individuals with sulfonylurea-sensitive permanent neonatal diabetes mellitus, attributable to a KCNJ11 mutation, and poor glycaemic control.
    Stanik J; Dankovcikova A; Barak L; Skopkova M; Palko M; Divinec J; Klimes I; Gasperikova D
    Diabet Med; 2018 Mar; 35(3):386-391. PubMed ID: 29278452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of diabetes phenotype in children and their mothers with permanent neonatal diabetes mellitus carrying the same
    Stanik J; Barak L; Dankovcikova A; Valkovicova T; Skopkova M; Gasperikova D
    Endocr Regul; 2020 Nov; 54(4):260-265. PubMed ID: 33885251
    [No Abstract]   [Full Text] [Related]  

  • 14. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes.
    Holstein A; Hahn M; Stumvoll M; Kovacs P
    Horm Metab Res; 2009 May; 41(5):387-90. PubMed ID: 19214942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulfonylurea in the treatment of neonatal diabetes mellitus children with heterogeneous genetic backgrounds.
    Zhang M; Chen X; Shen S; Li T; Chen L; Hu M; Cao L; Cheng R; Zhao Z; Luo F
    J Pediatr Endocrinol Metab; 2015 Jul; 28(7-8):877-84. PubMed ID: 25781672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DEND syndrome due to V59A mutation in KCNJ11 gene: unresponsive to sulfonylureas.
    Itoh S; Matsuoka H; Yasuda Y; Miyake N; Suzuki K; Yorifuji T; Sugihara S
    J Pediatr Endocrinol Metab; 2013; 26(1-2):143-6. PubMed ID: 23382304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical presentation and long-term outcome of patients with KCNJ11/ABCC8 variants: Neonatal diabetes or MODY in the DPV registry from Germany and Austria.
    Warncke K; Eckert A; Kapellen T; Kummer S; Raile K; Dunstheimer D; Grulich-Henn J; Woelfle J; Wenzel S; Hofer SE; Dost A; Holl RW
    Pediatr Diabetes; 2022 Nov; 23(7):999-1008. PubMed ID: 35822653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful transition to sulfonylurea in neonatal diabetes, developmental delay, and seizures (DEND syndrome) due to R50P KCNJ11 mutation.
    Peña-Almazan S
    Diabetes Res Clin Pract; 2015 Apr; 108(1):e18-20. PubMed ID: 25678012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilizing the KCNJ11 Gene Mutations in Spotting Egyptian Patients With Permanent Neonatal Diabetes Who Can Benefit From Treatment Shift.
    Ahmed DM; Abdel Dayem SM; Abdel Kader M; Khalifa RH; El-Lebedy DH; Kamel SA; Shawky SM
    Lab Med; 2017 Aug; 48(3):225-229. PubMed ID: 28460053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transfer from insulin to sulfonylurea treatment in a chinese patient with permanent neonatal diabetes mellitus due to a KCNJ11 R201H mutation.
    Xiao X; Wang T; Li W; Song H; Gong C; Diao C; Yu M; Yuan T; Zhang Y; Sun X; Zhang Q; Lu K; Wang H; Schmitz O; Hansen T
    Horm Metab Res; 2009 Jul; 41(7):580-2. PubMed ID: 19247925
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.